2018
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppression
2015
An exploratory study of therapeutic misconception among incarcerated clinical trial participants
Christopher PP, Stein MD, Springer SA, Rich JD, Johnson JE, Lidz CW. An exploratory study of therapeutic misconception among incarcerated clinical trial participants. AJOB Empirical Bioethics 2015, 7: 24-30. PMID: 26709382, PMCID: PMC4687735, DOI: 10.1080/23294515.2015.1058303.Peer-Reviewed Original Research